Neurocrine Biosciences : 2025 Corporate Responsibility Report

Published: 2025-07-07 15:01:07 ET NBIX

Published on 07/07/2025 at 15:01

2025

Corporate Responsibility Report

NEUROCRINE

''>P BIOSCIENCES

‌Table of Contents

About This Report

This Corporate Responsibility Report provides an overview of the governance, oversight, policies, programs, and performance around corporate responsibility topics important to Neurocrine Biosciences, Inc. ("Neurocrine Biosciences", "Neurocrine", "Company", "we", "our", or "us") and the Company's stakeholders. Unless otherwise specifically stated, this report covers Neurocrine's performance in fiscal 2024, ended December 31, 2024.

3 Letter From Our CEO

6

4 About Neurocrine Biosciences Our Approach to

Corporate Responsibility

8 Patients and Products

14 Our People

19 Our Communities

20 Our Environment

23 Integrity

26 Appendix

Letter From Our CEO

‌Kyle W. Gano, Ph.D.

Chief Executive Officer

Over the past year, Neurocrine Biosciences has continued to develop life-changing treatments to relieve suffering for people in need. We are rapidly advancing our diversified pipeline while executing on our commercial medicines for patients, positioning Neurocrine to drive sustainable growth and value for our shareholders.

While much has changed at Neurocrine since our founding in 1993, our culture remains grounded

in core values of passion, integrity, collaboration, innovation, and tenacity. After more than 23 years with the Company, and even more so in my new role as Chief Executive Officer, I continue to believe deeply in these values and how they drive our success.

I am pleased to present our 2025 Corporate Responsibility Report, highlighting the programs that support our vision of becoming the leading neuroscience company. We prioritize areas that represent the highest value to our business.

As outlined in our Code of Business Conduct and Ethics, our employees have a responsibility to "do well" and "do good" for patients, customers, partners, and shareholders - a principle that

applies to our approach to corporate responsibility. While our strong third-party ratings from MSCI and Sustainalytics validate our programs and efforts, we remain focused on continuously improving and striving to "do better" and drive long-term value.

Our people are the heart of Neurocrine and critical to our success. We continually invest in our training, development, and engagement programs to drive our employees' - and our company's - growth.

We are proud to maintain our status as a Great to Work® Certified company, recognizing our efforts to foster a positive and supportive culture.

As part of our efforts to drive efficiency and reduce our company's impact on the environment, we fully transitioned to our new LEED silver-eligible corporate headquarters in San Diego, where our scientists are diligently advancing the programs of tomorrow.

Thank you to our stakeholders, including our employees, patients, and shareholders, for your support and contributions to our company's success. We look forward to continuing to discover and develop life-changing treatments for our patients while cementing Neurocrine's position as a leader in neuroscience.

Sincerely,

3 Neurocrine Biosciences 2025 Corporate Responsibility Report < Return to ToC >

‌Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's portfolio of products includes U.S.

Food and Drug Administration (FDA) approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), endometriosis,* and uterine fibroids*. Additionally, we have

a diversified portfolio of multiple compounds in mid- to late-phase clinical development across our core therapeutic areas and an expanding early-phase pipeline that includes a range of modalities including small molecules, peptides, proteins, antibodies, and gene therapy. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information visit neurocrine.com, and follow the company on LinkedIn, X, and Facebook.

~$2.3B

2024 revenue

~1,800

Total employees

~11

Programs in clinical

development**

3

Phase 3

Programs

*In collaboration with AbbVie

**As of June 2025

4 Neurocrine Biosciences 2025 Corporate Responsibility Report < Return to ToC >

Our Values

PASSION

We are driven and love what we do. We are committed to our goals and to making a difference.

We do the right thing for patients and our community. We take accountability. We speak up.

INNOVATION

We seek and create optimal solutions.

TENACITY

We do not quit. We adapt.

We accomplish what others cannot.

COLLABORATION

We trust one another.

We are inclusive. We are respectful.

We are transparent. Together we succeed.

5 Neurocrine Biosciences 2025 Corporate Responsibility Report < Return to ToC >

Disclaimer

Neurocrine Biosciences Inc. published this content on July 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 07, 2025 at 19:00 UTC.